Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07215988 · ClinicalTrials.gov registry record

Studying Off Label Insurance Coverage for Patients With Cutaneous Cancers a "Filter" Observational Study

A clinical trial of Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 and Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, sponsored by Ohio State University Comprehensive Cancer Center.

Recruiting
Registry status
70
Enrollment target
1
Study location

NCT07215988 is a study of Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 and Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8 that is actively recruiting participants, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 70 participants, above the 22-participant average among 4 other Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 trials with a reported enrollment target (218% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07215988, a study of Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 and Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, is actively recruiting participants, sponsored by Ohio State University Comprehensive Cancer Center.

RECRUITING
Registry status
70 participants
Enrollment target
1
Study location

Study Summary

This study evaluates the time spent on obtaining insurance approval and drugs, means of insurance coverage, out-of-pocket costs for patients, and the surgical outcomes after neoadjuvant treatment is completed in skin cancer patients receiving "off label" and "on label" neoadjuvant treatment. "Neoadjuvant therapy" means cancer treatment given before surgery. However, in many instances, neoadjuvant therapy is used as an "off-label" approach for several types of skin cancers. "Off-label" means that the FDA has not yet approved its use for that type of cancer. Therefore, insurance approval of these "off-label" treatments could be delayed compared to label use, and "off-label" treatments may require several weeks of pre-authorization. There is evidence that the delayed start of cancer treatment can lead to poorer outcomes.

Interventions

  • OTHER Non-Interventional Study

Study Locations (1)

Ohio

  • Ohio State University Comprehensive Cancer Center - Columbus

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2026-01-25
Est. Completion 2027-12-31

What the Registry Record Tells You About NCT07215988

The ClinicalTrials.gov registry entry for NCT07215988 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 22-participant average among 4 other Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 trials with a reported enrollment target (218% higher). The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.

The record links to 8 conditions, with Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 appearing as the primary indexed condition, and to 1 intervention - of which Non-Interventional Study is the first listed.

NCT07215988 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT07215988 about?

NCT07215988 is a clinical study titled "Studying Off Label Insurance Coverage for Patients With Cutaneous Cancers a "Filter" Observational Study". This study evaluates the time spent on obtaining insurance approval and drugs, means of insurance coverage, out-of-pocket costs for patients, and the surgical outcomes after neoadjuvant treatment is completed in skin cancer patients receiving "off label" and "on label" neoadjuvant treatment. "Neoadj...

What is the current status of trial NCT07215988?

This trial is currently recruiting. The enrollment target is 70 participants. The study started on 2026-01-25. Estimated completion is 2027-12-31.

What conditions does trial NCT07215988 study?

This clinical trial studies the following conditions: Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, Locally Advanced Basal Cell Carcinoma, Locally Advanced Merkel Cell Carcinoma, Locally Advanced Mucosal Melanoma.

What interventions are being tested in trial NCT07215988?

The interventions under investigation include: Non-Interventional Study (OTHER).

Who is sponsoring clinical trial NCT07215988?

This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07215988 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.